Suchergebnisse - "Mason, Warren P"

PubPharm (194)

1

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

enthalten in: Molecular cancer therapeutics | 2024

von Lee, C. | O'Kane, G. | Mason, W. | +8

2

Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma

enthalten in: Neuro-oncology advances | 2024

von van der Meulen, M. | Ramos, R. | Voisin, M. | +11

3

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma : An Update

enthalten in: Current oncology (Toronto, Ont.) | 2023

von Alsajjan, R. | Mason, W.

4

The Value of Etoposide for Recurrent Glioma

enthalten in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques | 2023

von van der Meulen, M. | Chahal, M. | Mason, W.

5

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

enthalten in: The New England journal of medicine | 2023

von Mellinghoff, I. | van den Bent, M. | Blumenthal, D. | +119

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):737-738. - PMID 37460634

6

Bevacizumab for Cerebral Radionecrosis : A Single-Center Experience

enthalten in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques | 2023

von Climans, S. | Ramos, R. | Jablonska, P. | +2

7

BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets

enthalten in: CNS drugs | 2023

von Muniz, T. | Mason, W.

8

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma : a phase 1/2 trial

enthalten in: Nature medicine | 2023

von Nassiri, F. | Patil, V. | Yefet, L. | +36

9

BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets

enthalten in: CNS drugs | 2023

von Muniz, T. | Mason, W.

10

BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets

enthalten in: CNS drugs | 2023

von Muniz, T. | Mason, W.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]